Join Clinical Trials for Blood Diseases in Canada

All Categories Medical Conditions » Blood Disorders » Canada

Effects of HQK-1001 in Patients With Sickle Cell Disease

Conditions: Sickle Cell Disease; Sickle Cell Anemia; Sickle Cell Disorders; Hemoglobin S Disease; Sickling Disorder Due to Hemoglobin S
Interventions: Drug: HQK-1001; Drug: Placebo
Sponsors: HemaQuest Pharmaceuticals Inc.; HemaQuest Pharmaceuticals Inc.
Not yet recruiting - verified May 2012
Neuroblastoma Biology Study

Condition: Neuroblastoma
Intervention:
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2012
An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

Condition: Blood Coagulation Disorders
Intervention: Drug: Dabigatran Etexilate 110 mg
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada; Capital Health, Canada; Dalhousie University; Université de Montréal
Not yet recruiting - verified April 2012
LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression

Condition: Late Life Depression
Intervention: Drug: Mirtazapine
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Not yet recruiting - verified May 2012
Endoscopic Band Ligation Versus Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial

Condition: Gastric Antral Vascular Ectasia
Interventions: Device: Endoscopic Band Ligation; Device: Argon plasma Coagulation (APC) for GAVE
Sponsors: University of Alberta; University of Alberta
Not yet recruiting - verified May 2012
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012
Lifestyle Therapy for Youth With Type 2 Diabetes

Condition: Type 2 Diabetes Mellitus
Intervention: Behavioral: Lifestyle Counselling
Sponsors: University of Manitoba; University of Manitoba; Manitoba Institute of Child Health
Not yet recruiting - verified May 2012
Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study

Condition: Type 1 Diabetes
Intervention: Device: Pump suspension
Sponsors: In Home Closed Loop Study Group; In Home Closed Loop Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2012
Cannabis Effects on Driving-related Skills of Young Drivers

Condition: Psychomotor Impairment
Interventions: Drug: delta-9-tetrahydrocannabinol; Drug: Placebo
Sponsors: Centre for Addiction and Mental Health; Centre for Addiction and Mental Health; Canadian Institutes of Health Research (CIHR); Health Canada
Not yet recruiting - verified May 2012
Low Glycaemic Index (GI) Diet in the Management of GDM

Condition: Gestational Diabetes Mellitus
Interventions: Other: Low GI diet; Other: Standard Care
Sponsors: University of Toronto; University of Toronto; Canadian Diabetes Association; Canadian Institutes of Health Research (CIHR); Canadian Foundation for Dietetic Research (CFDR)
Recruiting - verified April 2012
A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: ASKP1240; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.; Kyowa Hakko Kirin Company, Limited
Recruiting - verified April 2012
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

Condition: Hypertension
Intervention: Drug: Aliskiren
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Near-infrared Spectroscopic Measurement in Complex Regional Pain Syndrome

Condition: Reflex Sympathetic Dystrophy
Intervention:
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified April 2012
Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury

Conditions: Spinal Cord Injuries; Muscle Spasticity
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified April 2012
The Effect of High Frequency Oscillation on Biological Markers of Lung Injury

Condition: Acute Respiratory Distress Syndrome
Intervention:
Sponsors: Canadian Critical Care Trials Group; Canadian Critical Care Trials Group; Canadian Intensive Care Foundation
Recruiting - verified April 2012
Whole Milk Versus Whey Protein Supplement and Resistance Exercise

Condition: Muscle Development
Interventions: Dietary Supplement: Whey protein; Dietary Supplement: Chocolate milk; Dietary Supplement: Sugar
Sponsors: University of Manitoba; University of Manitoba
Recruiting - verified April 2012
Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate

Condition: Vitamin B12 Deficiency
Interventions: Dietary Supplement: L-5-methyltetrahydrofolate (Metafolin ®); Dietary Supplement: folic acid; Dietary Supplement: Placebo
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified April 2012
Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes

Conditions: Diabetes Mellitus Type 2; Hypertension
Interventions: Dietary Supplement: Combined Rg3-enriched Korean Red Ginseng (panax Ginseng C.A. Meyer) and American Ginseng (panax Quinquefolius).; Dietary Supplement: 100% Natural Wheat Bran
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Canadian Diabetes Association
Recruiting - verified April 2012
Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial

Condition: Type 1 Diabetes
Interventions: Drug: Statin; Drug: Ace Inhibitor; Drug: Placebo; Drug: Combination therapy
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Juvenile Diabetes Research Foundation; Diabetes UK; British Heart Foundation; Pfizer; The University of Western Australia; The Hospital for Sick Children; University of Oxford; St Thomas' Hospital, London
Recruiting - verified April 2012
Healthy Moms, Healthy Babies

Conditions: Type 2 Diabetes Mellitus; Gestational Diabetes
Interventions: Device: Continuous Glucose Monitoring; Device: Glucose Meter
Sponsors: Lawson Health Research Institute; Dr. Stewart Harris; Juvenile Diabetes Research Foundation
Not yet recruiting - verified April 2012
Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors

Conditions: Hypertension; Hypercholesterolemia; Type II Diabetes; Obesity; Inflammation
Intervention: Other: vegetable
Sponsors: University of Guelph; University of Guelph; Ontario Ministry of Agriculture, Food and Rural Affairs
Not yet recruiting - verified March 2012
Dual Task Aerobic Exercise for Older Adults With Cognitive Impairment

Condition: Cognitive Impairment
Interventions: Other: Dual task gait training; Other: Dual task gait training; Other: Aerobic exercise class
Sponsors: Parkwood Hospital, London, Ontario; Parkwood Hospital, London, Ontario; University of Western Ontario, Canada; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified April 2012
Bowel Care and Cardiovascular Function After Spinal Cord Injury

Condition: Spinal Cord Injury
Interventions: Drug: Lidocaine lubricant; Other: Placebo lubricant
Sponsors: Simon Fraser University; Simon Fraser University; University of British Columbia
Recruiting - verified March 2012
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects

Condition: Drug Mechanism
Intervention: Drug: Lithium Carbonate
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Not yet recruiting - verified April 2012
The Effects of Tai Chi in Older Patients With Cardiovascular Disease

Condition: Cardiovascular Disease
Interventions: Behavioral: Tai Chi exercise; Behavioral: Sham Exercise
Sponsors: McMaster University; McMaster University; Heart and Stroke Foundation of Ontario; Hamilton Health Sciences Corporation
Recruiting - verified May 2012
Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis

Condition: Colorectal Cancer.
Intervention: Radiation: Stereotactic body radiotherapy
Sponsors: Sunnybrook Health Sciences Centre; Dr. Yoo-Joung Ko; Roche Pharma AG
Recruiting - verified April 2012
Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation

Condition: Menorrhagia
Interventions: Device: Aurora Endometrial Ablation; Device: Rollerball Ablation/Resection
Sponsors: Minerva Surgical, Inc.; Minerva Surgical, Inc.
Recruiting - verified April 2012
Left Atrial Appendage Occlusion Study III

Conditions: Cardiac Surgery With Cardiopulmonary Bypass; Atrial Fibrillation
Intervention: Other: Left Atrial Appendage Occlusion
Sponsors: McMaster University; Population Health Research Institute
Not yet recruiting - verified March 2012
A Human Trial to Assess the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Soy

Conditions: Hypercholesterolemia; Cardiovascular Disease; CRP
Intervention: Other: Standardized soy containing muffin
Sponsors: Guelph Food Research Centre; Guelph Food Research Centre; University of Guelph; Glycemic Index Laboratories, Inc; Canadian Centre for Agri-food Research in Health and Medicine
Not yet recruiting - verified March 2012
Continuation Study of the Oral AKT Inhibitor GSK2110183

Condition: Cancer
Intervention: Drug: GSK2110183
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia

Condition: Hypoglycemia
Interventions: Drug: glucagon; Drug: low dose experimental formulation; Drug: high dose experimental formulation; Drug: Medium dose experimental glucagon formulation
Sponsors: AMG Medical Inc.; AMG Medical Inc.
Recruiting - verified May 2012
Study of Coronary Plaque Rupture in Heart Attack Following Surgery Using Optical Coherence Tomography (OCT)

Conditions: Peri-operative Myocardial Infarction; Non-ST Elevation Myocardial Infarction
Intervention:
Sponsors: Hamilton Health Sciences Corporation; Victar Hsieh
Recruiting - verified April 2012
Randomized Controlled Trial of Milk Products and Physical Activity on Body Composition and Health in Overweight Young Males

Condition: Overweight
Interventions: Other: Increased Dairy Intake; Other: Supplemental carbohydrate
Sponsors: Brock University; Brock University
Not yet recruiting - verified March 2012
A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas

Condition: Neoplasms
Intervention: Drug: Aneustat (OMN54)
Sponsors: Omnitura Therapeutics, Inc.; Omnitura Therapeutics, Inc.
Not yet recruiting - verified March 2012
e-Counseling Promotes Blood Pressure Reduction and Therapeutic Lifestyle Change in Hypertension

Condition: Hypertension
Interventions: Behavioral: e-Counseling plus Usual Care; Behavioral: Control
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified January 2012
Testing the Developmental Origins Hypothesis

Conditions: Diabetes; Stroke; Obesity
Intervention:
Sponsors: Children's & Women's Health Centre of British Columbia; Children's & Women's Health Centre of British Columbia
Recruiting - verified March 2012
TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment

Condition: Latent Tuberculosis Infection
Intervention: Other: Cell phone text messages
Sponsors: University of British Columbia; University of British Columbia; British Columbia Cancer Agency
Not yet recruiting - verified March 2012
Renin and Aldosterone Levels in the Preterm Neonate At Risk for Hypertension

Conditions: Hypertension; Diabetes; Infants Small for Gestational Age
Intervention:
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; The Physicians' Services Incorporated Foundation
Not yet recruiting - verified March 2012
Predicting Response to Standardized Pediatric Colitis Therapy

Condition: Ulcerative Colitis
Interventions: Drug: Mesalamine; Drug: Prednisone; Drug: Corticosteroids followed by mesalamine (Pentasa)
Sponsors: Connecticut Children's Medical Center; Connecticut Children's Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified April 2012
In-human Validation of a Technique for Measuring Central Aortic Hemodynamics With Peripheral Arterial Waveforms

Condition: Coronary Artery Disease
Intervention: Procedure: BP Measurements at aorta, radial and femoral locations
Sponsors: University of Alberta; University of Alberta
Recruiting - verified March 2012
Where Should Automated Blood Pressures be Done in Primary Care Offices?

Condition: Hypertension
Intervention:
Sponsors: North Toronto Primary Care Research Network; North Toronto Primary Care Research Network
Not yet recruiting - verified April 2012
The Effects of Cardiac Rehabilitation on Cardiovascular Disease Risk in Rheumatoid Arthritis Patients

Condition: Rheumatoid Arthritis
Intervention: Behavioral: Exercise
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Not yet recruiting - verified February 2012
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

Conditions: Down Syndrome; Fetal Aneuploidy
Intervention:
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2012
Examining the Impact of Using Two Dialysers in Parallel on Dialysis Adequacy in Hemodialysis Patients

Condition: End Stage Renal Disease
Interventions: Procedure: Standard treatment; Procedure: Two dialyzers
Sponsors: University of Alberta; University of Alberta; University of Calgary
Not yet recruiting - verified February 2012
Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Other: Submaximal exercises
Sponsors: Laval University; Laval University
Recruiting - verified January 2012
Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Conditions: Overactive Bladder; Neurogenic Detrusor Overactivity
Intervention: Drug: Solifenacin succinate
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Not yet recruiting - verified February 2012
INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Conditions: Myelofibrosis; Post Polycythemia Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
Sponsors: Novartis; Novartis Pharmaceuticals
Available - verified December 2011
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Brain-Derived Neurotrophic Factor in Obesity and Brain Function

Conditions: Obesity; Genetic Disorder; Mental Retardation; Developmental Delay
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2011
Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS

Conditions: Kidney Failure Chronic; Cardiovascular Diseases
Intervention: Device: Hemocontrol
Sponsors: Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
Not yet recruiting - verified February 2012
Tissue Near InfraRed Spectroscopy (NIRS) in Critically Ill Patients

Conditions: Sepsis; Inflammation; Shock
Intervention:
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; The Physicians' Services Incorporated Foundation
Not yet recruiting - verified February 2012
Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-moderate Hypertriglyceridemia

Condition: Hypertriglyceridemia
Interventions: Dietary Supplement: CaPre™; Dietary Supplement: CaPre™; Dietary Supplement: CaPre™; Other: Standard of care
Sponsors: Acasti Pharma Inc.; Acasti Pharma Inc.; JSS Medical Research Inc.
Recruiting - verified January 2012
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Nodes Using Pet-Ct, CT-Perfusion and 3T MRI

Condition: Rectal Cancer
Intervention: Device: MRI,PET-CT and CT-Perfusion studies
Sponsors: London Health Sciences Centre; London Health Sciences Centre
Not yet recruiting - verified January 2012
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke

Conditions: Stroke; Ischemic Attack, Transient; Sleep Disorders; Sleep Apnea Syndromes; Restless Legs Syndrome
Interventions: Other: Expedited Treatment of Sleep Disorders; Other: Standard of Care
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Canada; Canadian Stroke Network; Sunnybrook Research Institute
Recruiting - verified February 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Evaluation of the SickKids Team Obesity Management Program

Condition: Obesity
Intervention: Behavioral: STOMP Clinic
Sponsors: The Hospital for Sick Children; The Hospital for Sick Children
Recruiting - verified January 2012
A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer

Conditions: Pancreatic Cancer; Hypoxia
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Cancer Society
Recruiting - verified March 2012
Iron Treatment for Young Children With Non-anemic Iron Deficiency

Condition: Non-anemic Iron Deficiency
Interventions: Dietary Supplement: Ferrous Sulfate; Dietary Supplement: Placebo; Other: No intervention; Behavioral: Dietary counseling
Sponsors: The Hospital for Sick Children; The Hospital for Sick Children; Canadian Institutes of Health Research (CIHR); Mead Johnson Nutrition; Mount Sinai Hospital, Canada; St. Michael's Hospital, Toronto
Not yet recruiting - verified November 2011
Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Conditions: Colon Cancer; Rectal Cancer
Intervention:
Sponsors: University of Michigan; University of Michigan; Early Detection Research Network
Recruiting - verified January 2012
Philips Pivotal Clinical Trial for MRI-HIFU of Uterine Fibroids

Condition: Uterine Fibroids
Interventions: Device: MR-HIFU treatment for ablation of uterine fibroids; Device: Sham HIFU treatment
Sponsors: Philips Healthcare; Philips Healthcare
Not yet recruiting - verified May 2012
The Effect of Two Airway Interventions, During One Lung Ventilation, on Blood Oxygen Content

Condition: Thoracic, Diseases
Interventions: Procedure: RM + Positive End Expiratory Pressure; Procedure: Continuous Positive Airway Pressure
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Not yet recruiting - verified December 2011
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Conditions: Dyskinesias; Parkinson Disease; Movement Disorders; Parkinsonian Disorders; Anti-Dyskinesia Agents
Interventions: Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia

Condition: Hemophilia A
Intervention: Other: Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention
Sponsors: The Hospital for Sick Children; The Hospital for Sick Children
Not yet recruiting - verified November 2011
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma

Condition: Multiple Myeloma
Intervention: Drug: ABT-888/Bortezomib
Sponsors: Alberta Health Services; Alberta Health Services; Tom Baker Cancer Centre; Abbott
Recruiting - verified December 2011
Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury

Condition: Orthostatic Intolerance
Intervention: Drug: Midodrine
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified December 2011
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Conditions: Dyskinesias; Parkinson Disease; Movement Disorders; Parkinsonian Disorders; Anti-Dyskinesia Agents
Intervention: Drug: AFQ056
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients

Condition: Infertility
Interventions: Drug: Nimodipine; Drug: Placebo
Sponsors: Mount Sinai Hospital, Canada; Mount Sinai Hospital, Canada
Not yet recruiting - verified April 2012
Impact of Pulse-enriched Foods on Cognitive Function and Cardiometabolic Health in Obese Adults

Condition: Obesity
Interventions: Other: Pulse Group; Other: Active Comparator
Sponsors: University of Manitoba; University of Manitoba; University of South Australia
Not yet recruiting - verified December 2011
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases

Conditions: Pain; Neoplasm Metastasis
Intervention: Procedure: Cryoablation
Sponsors: Galil Medical; Galil Medical
Recruiting - verified April 2012
Step Monitoring to Improve ARTERial Health

Conditions: Type 2 Diabetes; Hypertension
Interventions: Behavioral: Step count prescription; Behavioral: Usual care
Sponsors: McGill University Health Center; McGill University Health Center; Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2012
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified December 2011
Management of Hypotension In the Preterm

Conditions: Hypotension; Low Blood Pressure; Prematurity of Fetus
Interventions: Drug: Dopamine hydrochloride; Drug: Dextrose 5%
Sponsors: University College Cork; University College Cork; BrePco Biopharma Limited; Cork University Hospital; Katholieke Universiteit Leuven; Univerzita Karlova v Praze; Centre hospitalier universitaire Sainte-Justine; University College Dublin; Coombe Women and Infants University Hospital; University of Alberta; Royal College of Surgeons, Ireland; GABO:milliarium mbH & Co. KG; National de la Santé et de la Recherche Medicale; University College, London; Clininfo S.A.
Not yet recruiting - verified November 2011
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011
Urine Metabolomics and Colorectal Cancer Screening

Conditions: Colorectal Cancer; Colorectal Polyps
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified December 2011
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Tadalafil- Tablet
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury

Condition: Spinal Cord Injury
Intervention: Drug: SPINALON (buspirone + levodopa + cardidopa)
Sponsors: Nordic Life Science Pipeline Inc.; Nordic Life Science Pipeline Inc.; Department of Defense
Not yet recruiting - verified December 2011
Nilotinib and LDE225 in the Treatment of Phase Chronic Myeloid Leukemia Patients Who Developed Resistance to Prior Therapy

Condition: Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib + LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring

Condition: Gestational Diabetes Mellitus
Intervention:
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Eli Lilly and Company
Recruiting - verified December 2011
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

Conditions: Adenocarcinoma of the Pancreas; Metastatic Disease
Intervention: Drug: AUY922
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Novartis Pharmaceuticals
Not yet recruiting - verified January 2012
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012
What Needle Diameter Should Physician Use When They Perform Lumbar Puncture ? A Randomized Controlled Trial

Conditions: Post-lumbar Puncture Headache; Backache
Interventions: Device: whitacre 24 gauge; Device: whitacre 22 gauge
Sponsors: McGill University; McGill University; funding: McGill Emergency Medicine 2010 Grant Competition
Recruiting - verified November 2011
Assessing Vein Graft Properties Between Conventional & No-Touch Harvesting Technique - (PATENT SVG)

Condition: Coronary Artery Disease
Interventions: Procedure: Pedicled "no-touch" SVG harvesting; Procedure: Conventional open SVG harvesting
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; St. Michael's Hospital, Toronto
Recruiting - verified December 2011
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis

Conditions: Chronic Obstructive Pulmonary Diseases; Chronic Airways Limitation; Bronchitis
Interventions: Drug: Mepolizumab; Drug: placebo
Sponsors: McMaster University; McMaster University
Recruiting - verified October 2011
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects

Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
The Young Women's Breast Cancer Study

Condition: Breast Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified November 2011
A First-In-Human Study of RO5503781 in Patients With Advanced Malignancies, Except Leukemia

Condition: Neoplasms
Interventions: Drug: RO5503781; Drug: RO5503781
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia

Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention:
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified February 2012
Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colon Cancer

Condition: Adenocarcinoma of the Colon
Interventions: Drug: Tinzaparin; Drug: Tinzaparin
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified October 2011
Health Coaching to Effect Lifestyle Behaviour Change

Conditions: Prediabetes; Prehypertension
Intervention: Behavioral: Health Coaching
Sponsors: Memorial University of Newfoundland; Marshal Godwin; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified October 2011
A Study in Patients With Type I Diabetes Mellitus

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Condition: Thrombocytopaenia
Interventions: Drug: eltrombopag; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy

Conditions: Colonic Neoplasms; Iron Deficiency Anemia; Diarrhea
Intervention: Device: Olympus ScopeGuide
Sponsors: University of Alberta; Christopher Teshima
Recruiting - verified April 2012
A Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound

Condition: Subsegmental (Single or Multiple) Pulmonary Embolism
Intervention:
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified October 2011
The Plasma Large-Volume Exchange RCT

Conditions: Purpura, Thrombotic Thrombocytopenic; Hemolytic Uremic Syndrome
Intervention: Procedure: Plasma Exchange
Sponsors: London Health Sciences Centre; London Health Sciences Centre
Not yet recruiting - verified September 2011
Efficacy of a Physiotherapy Treatment in Women Suffering From Provoked Vestibulodynia

Condition: Vestibulodynia
Interventions: Procedure: Multimodal physiotherapy; Drug: lidocaine
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Canadian Institutes of Health Research (CIHR); Fonds de la Recherche en Santé du Québec
Recruiting - verified October 2011
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy

Condition: Peanut Allergy
Interventions: Drug: QGE031; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012
Impact of Dairy Consumption on Inflammation: a Clinical Study (PLI)

Condition: Cardiovascular Disease
Intervention: Other: Dairy
Sponsors: Laval University; Laval University; Dairy Farmers of Canada
Recruiting - verified May 2012
Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV

Condition: Vasovagal Syncope
Interventions: Drug: midodrine hydrochloride; Drug: matching placebo
Sponsors: University of Calgary; Dr. Bob Sheldon; Vanderbilt University
Recruiting - verified January 2012
A Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified April 2012
15-Degree Tilt, Head Up, Feet Down Body Position for Sinus Surgery Patients

Condition: Sinusitis
Intervention: Procedure: Reverse Trendelenburg Position
Sponsors: St. Paul's Hospital, Canada; St. Paul's Hospital, Canada
Not yet recruiting - verified October 2011
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
A Prospective Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer

Condition: Thyroid Neoplasms
Interventions: Drug: CPERT; Drug: GPERT
Sponsors: Alberta Health Services; Alberta Health Services; Natural Resources, Canada; Edmonton PET Centre
Recruiting - verified April 2012
A Study in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
A Trial Comparing The Efficacy And Safety Of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing

Conditions: Hematopoietic Stem Cell Transplant; Hematologic Malignancy; Voriconazole
Intervention: Drug: Prospective Voriconazole therapeutic drug monitoring
Sponsors: Johns Hopkins University; Johns Hopkins University; Pfizer
Not yet recruiting - verified July 2011
Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Conditions: Respiratory Tract Infections; Bronchiolitis Obliterans; Cryptogenic Organizing Pneumonia; Lung Diseases, Interstitial
Interventions: Drug: Prednisone; Drug: Azithromycin; Drug: Montelukast; Drug: Symbicort
Sponsors: Maisonneuve-Rosemont Hospital; Maisonneuve-Rosemont Hospital; The Canadian Blood and Marrow Transplant Group
Recruiting - verified January 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment and Prevention of Bleeding Episodes in Von Willebrand Disease (VWD)

Condition: Von Willebrand Disease
Intervention: Biological: Recombinant von Willebrand factor (rVWF) with or without rFVIII (Advate)
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation; Baxter Innovations GmbH
Recruiting - verified March 2012
Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia

Condition: Bronchopulmonary Dysplasia
Intervention:
Sponsors: St. Justine's Hospital; St. Justine's Hospital; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified September 2011
Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients

Condition: End Stage Renal Disease
Intervention:
Sponsors: University of Alberta; University of Alberta; Massachusetts General Hospital
Recruiting - verified May 2012
Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy

Conditions: Down Syndrome; Fetal Aneuploidy
Intervention:
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified February 2012
Clinical Assessment of Thrombosis in Children After Heart Surgery

Condition: Thrombosis
Intervention: Procedure: Cardiac Surgery
Sponsors: The Hospital for Sick Children; The Hospital for Sick Children
Recruiting - verified September 2011
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children : the PREDICT Pharmacogenetics Validation Study

Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012
A Phase III Study to Evaluate Safety, Tolerability and Efficacy of CureXcell™ in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus

Conditions: Lower Extremity Chronic Ulcers; Diabetes Mellitus
Interventions: Biological: Curexcell; Biological: Sham injection
Sponsors: Macrocure Ltd.; Macrocure Ltd.; Averion International Corporation
Recruiting - verified September 2011
Hypoalbuminemia in Burn Patients

Condition: Second or Third Degree Burns
Intervention: Drug: 5% human albumin solution (HAS)
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Not yet recruiting - verified September 2011
TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care

Conditions: Diabetes Mellitus, Type 2; Hypertension; Dyslipidemias; Cholesterol, LDL; Comorbitdity
Interventions: Other: Facilitation; Other: Passive diffusion (usual implementation strategy)
Sponsors: Fonds de la Recherche en Santé du Québec; Fonds de la Recherche en Santé du Québec; Université de Montréal
Recruiting - verified August 2011
Safety Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Conditions: Primary Myelofibrosis; Post-Polycythemia Vera; Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
Sponsors: YM BioSciences Australia Pty Ltd.; YM BioSciences Australia Pty Ltd.
Recruiting - verified April 2012
SHoC-ED 1: A Study on the Effects of Ultrasound on Hypotensive Patients in the ER and Patient Outcomes

Condition: Hypotension
Intervention: Device: Ultrasound
Sponsors: Saint John Regional Hospital; Saint John Regional Hospital
Recruiting - verified March 2012
The Risk of Venous Clotting in Patients After Renal Transplant

Conditions: Venous Thrombosis; End Stage Renal Failure With Renal Transplant; Deep Vein Thrombosis; Pulmonary Embolism
Intervention:
Sponsors: St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton; Astellas Pharma Canada, Inc.
Recruiting - verified August 2011
3-Month Trial Observation of A1c Change

Condition: Type 2 Diabetes
Intervention: Other: Internet Communication
Sponsors: Endocrine Research Society; Endocrine Research Society
Recruiting - verified October 2011
Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans

Conditions: Renin Angiotensin System; Human; Renal Hemodynamics
Intervention: Dietary Supplement: Fructose
Sponsors: University of Calgary; University of Calgary
Recruiting - verified July 2011
Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes

Conditions: Diabetes Mellitus; Overweight; Obesity
Intervention: Dietary Supplement: Salba (Salvia hispanica L.)
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Canadian Diabetes Association
Recruiting - verified June 2009
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tretinoin and Arsenic Trioxide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Northwestern University; New York Presbyterian Hospital; University of Southern California; Princess Margaret Hospital, Canada; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia

Conditions: Obstetric Anesthesia; Spinal Anesthesia; Hypotension; Fluid Therapy; Cesarean Section
Intervention: Drug: Hydroxyethylstarch 130/0.4
Sponsors: Maisonneuve-Rosemont Hospital; Maisonneuve-Rosemont Hospital; Université de Montréal
Recruiting - verified April 2012
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy

Condition: Kidney Neoplasms
Interventions: Device: Quill knotless tissue-closure device; Device: 2-0 absorbable vicryl suture
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Not yet recruiting - verified August 2011
Multi-modality Imaging of Ischemia With 18F-FDG PET and CTA

Condition: Myocardial Ischemia
Intervention: Radiation: 18F-Fluorodeoxyglucose
Sponsors: University of Ottawa Heart Institute; University of Ottawa Heart Institute
Recruiting - verified March 2012
Levofloxacin in Preventing Infection in Young Patients Receiving Chemotherapy For Acute Leukemia or Undergoing Stem Cell Transplantation

Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression

Conditions: Bipolar Disorder; Bipolar Depression; Bipolar I Depression; Bipolar II Depression
Intervention: Drug: Minocycline
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified July 2011
Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor

Condition: Malignant Lymphoma, Stem Cell Type
Interventions: Drug: Plerixafor (Mozobil); Drug: Plerixafor + G-CSF
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada; Genzyme
Not yet recruiting - verified July 2011
Managing Diabetes During Pregnancy in the Wireless Age

Conditions: Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus
Intervention: Device: Home Blood Glucose Telemonitoring System
Sponsors: Samuel Lunenfeld Research Institute, Mount Sinai Hospital; Samuel Lunenfeld Research Institute, Mount Sinai Hospital; Ontario Ministry of Health and Long Term Care
Recruiting - verified November 2011
Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray

Condition: Chronic Rhinosinusitis
Interventions: Device: Mucosal Atomization Device (MAD); Device: Budesonide via Nasal Syringe
Sponsors: St. Paul's Hospital, Canada; St. Paul's Hospital, Canada
Not yet recruiting - verified January 2011
Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations

Condition: Healthy
Interventions: Drug: Trazodone; Drug: Quetiapine; Drug: Pindolol; Procedure: Blood Collection
Sponsors: University of Ottawa; University of Ottawa
Recruiting - verified July 2011
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Conditions: Type 2 Diabetes Mellitus; High HbA1c Level; Inadequate Glycaemic Control
Interventions: Drug: dapagliflozin; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb
Recruiting - verified May 2012
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Conditions: Transfusional Iron Overload; Beta-Thalassemia
Intervention: Drug: FBS0701
Sponsors: FerroKin BioSciences, Inc.; FerroKin BioSciences, Inc.
Recruiting - verified August 2011
Effects of Pulse Types and Varieties on Blood Vessel Function

Condition: Peripheral Artery Disease
Interventions: Other: control foods; Other: Mixed bean (higher amount); Other: Mixed beans (lower amount)
Sponsors: University of Manitoba; University of Manitoba; Pulse Canada
Recruiting - verified March 2012
Femoral Bone Metastases

Conditions: Cancer; Metastatic Malignant Neoplasm to Femur; Risk of Fracture
Interventions: Procedure: Surgery Alone; Other: Combined Surgery and Radiation therapy
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified May 2012
Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain

Condition: Neuropathic Pain.
Intervention:
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified June 2011
Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia

Condition: Cardiac Arrest
Interventions: Drug: amiodarone; Drug: Lidocaine; Other: Normal saline
Sponsors: University of Washington; University of Washington; National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Canada; American Heart Association; Defence Research and Development Canada; U.S. Army Medical Research and Materiel Command
Not yet recruiting - verified February 2012
RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol

Conditions: Reflux; Gastroesophageal Reflux Disease (GERD)
Intervention:
Sponsors: Duke University; Duke University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Motivational Intervention for Asthma

Condition: Asthma
Interventions: Behavioral: Motivational Interviewing; Behavioral: Control
Sponsors: Hopital du Sacre-Coeur de Montreal; Hopital du Sacre-Coeur de Montreal; Jewish General Hospital
Recruiting - verified October 2011
Increasing Colorectal Cancer Screening Uptake With a Patient Navigator

Condition: Colorectal Cancer
Interventions: Behavioral: Health counselling by nurse navigator; Behavioral: Usual primary care counselling
Sponsors: Cancer Care Ontario; Cancer Care Ontario; Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2012
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Condition: Rheumatoid Arthritis
Intervention: Other: Observational study
Sponsors: Canadian Research & Education in Arthritis; Canadian Research & Education in Arthritis; Abbott
Recruiting - verified November 2011
Patients Treated for SCID (1968-2010)

Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified November 2011
Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension

Condition: Pulmonary Hypertension
Interventions: Drug: Vasopressin infusion; Drug: Vasopressin infusion and epoprostenol inhalation
Sponsors: University of Alberta; University of Alberta
Recruiting - verified May 2012
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes

Condition: Age Related Macular Degeneration
Intervention: Drug: Ranibizumab
Sponsors: McMaster University; McMaster University; Canadian National Institute for the Blind
Not yet recruiting - verified May 2011
The Quietude Study: Quetiapine Use for Agitated Depression

Condition: Depression With Prominent Agitation
Interventions: Drug: Quetiapine XR; Drug: Escitalopram
Sponsors: Physicians Research And Education Network; Physicians Research And Education Network
Recruiting - verified May 2011
Studies of Blood DNA in Patients With Severe Infection DYNAMICS

Conditions: Sepsis; Shock; Trauma
Intervention:
Sponsors: Hamilton Health Sciences Corporation; Hamilton Health Sciences Corporation
Recruiting - verified August 2011
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy

Condition: Stroke
Interventions: Biological: rfVIIa; Other: Standard saline solution
Sponsors: Sunnybrook Health Sciences Centre; Dr. David Gladstone; Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2012
Continuous Chest Compressions

Condition: Out of Hospital Cardiac Arrest
Interventions: Other: Comparison of 30:2 CPR versus continuous chest compressions; Other: Continuous chest compressions
Sponsors: University of Washington; University of Washington; National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Canada; American Heart Association; Defence Research and Development Canada; U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2012
Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study

Conditions: Disease Due to BK Polyomavirus; Kidney Transplant Infection
Intervention: Drug: Levofloxacin
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR); St. Paul's Hospital, Canada; Vancouver General Hospital; University of Alberta; University of Manitoba; University Health Network, Toronto; St. Michael's Hospital, Toronto; St. Joseph's Healthcare Hamilton; London Health Sciences Centre; McGill University Health Center; Dalhousie University
Recruiting - verified March 2012
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: MLN9708 plus Melphalan and Prednisone; Drug: MLN9708 plus Melphalan and Prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia

Conditions: Pre-Eclampsia; Pregnancy; Hypertension
Intervention: Drug: Nifedipine
Sponsors: Samuel Lunenfeld Research Institute, Mount Sinai Hospital; Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Recruiting - verified March 2012
TMC435HPC3002 - 3-Year Follow up of Patients After Administration of TMC435 for the Treatment of Chronic Hepatitis C.

Condition: Hepatitis C
Intervention: Other: Blood samples
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: pomalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified May 2012
Sepsis and Abdominal Drainage

Conditions: Abdominal Compartment Syndrome; Intra-abdominal Hypertension
Interventions: Device: KCI AbThera; Device: "Stampede" VAC
Sponsors: University of Calgary; University of Calgary; KCI USA, Inc.; Alberta Health Services
Recruiting - verified March 2012
Switch to Unboosted Atazanavir With Tenofovir Study

Condition: HIV Infection
Interventions: Drug: atazanavir; Drug: atazanavir/ritonavir
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified September 2011
Clopidogrel and Aspirin Interaction Study-2

Condition: Drug Action Increased
Interventions: Drug: Clopidogrel; Drug: Aspirin; Drug: Aspirin
Sponsors: Population Health Research Institute; Yan Liang
Recruiting - verified September 2011
Metformin in Women With Type 2 Diabetes in Pregnancy Trial

Condition: Type 2 Diabetes
Interventions: Drug: Metformin; Drug: Placebo Comparator
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Institutes of Health Research (CIHR); Mount Sinai Hospital, Canada
Recruiting - verified June 2011
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Conditions: Myocardial Infarction; Segment Elevation Myocardial Infarction (STEMI)
Interventions: Drug: Ticagrelor; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified September 2011
Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis

Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF)

Condition: Cancer Survivor
Interventions: Drug: carvedilol; Other: placebo; Other: pharmacogenomic studies; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Genetic: polymorphism analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study to Compare Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung

Conditions: Acute Lung Injury; Acute Respiratory Distress Syndrome
Interventions: Drug: IV Ganciclovir and Valganciclovir; Drug: Placebo
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI); Genentech
Recruiting - verified March 2012
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients

Conditions: Renal Disease; Renal Transplant
Interventions: Drug: Tacrolimus - Prograf® twice daily formulation; Drug: Tacrolimus - Advagraf® once daily formulation
Sponsors: University of British Columbia; University of British Columbia; Simon Fraser University; Astellas Pharma Canada, Inc.
Recruiting - verified November 2011
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Roflumilast; Drug: Placebo
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012
Pharmacist Intervention for Glycemic Control in The Community

Condition: Type 2 Diabetes
Intervention: Drug: Insulin glargine
Sponsors: University of Alberta; University of Alberta; Sanofi-Aventis
Recruiting - verified December 2011
Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases

Condition: Bone Metastasis
Intervention: Device: Philips MR-guided HIFU system
Sponsors: Philips Healthcare; Philips Healthcare
Recruiting - verified December 2011
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Point of Care HbA1c as a Screening Test for Type 2 Diabetes in First Nations

Condition: Type 2 Diabetes
Interventions: Procedure: Point-of-care "finger-poke" HbA1c determination.; Procedure: HbA1c blood test; Procedure: HbA1c finger poke test; Procedure: Blood test; Procedure: Blood test
Sponsors: University of British Columbia; University of British Columbia; Vancouver General Hospital
Recruiting - verified April 2012
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)

Condition: Renal Failure Chronic Requiring Hemodialysis
Interventions: Drug: Soluble Ferric Pyrophosphate (SFP); Device: Standard dialysate
Sponsors: Rockwell Medical Technologies, Inc.; Rockwell Medical Technologies, Inc.
Recruiting - verified April 2012
BAY81-8973 Pediatric Safety and Efficacy Trial

Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Conditions: Cryopyrin-associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle-Wells Syndrome; Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients

Conditions: Death; Stroke; Low Cardiac Output Syndrome; Myocardial Infarction; Renal Failure; Pulmonary Failure
Interventions: Other: Remote ischemic preconditioning stimulus; Other: control
Sponsors: Queen's University; Queen's University
Recruiting - verified March 2012
HepZero:Heparin Free Dialysis With Evodial

Conditions: Chronic Kidney Disease; Patients Requiring Heparin Free Dialysis Treatments
Interventions: Other: Heparin free dialysis technique; Device: Evodial
Sponsors: Gambro Lundia AB; Gambro Lundia AB; Statistical Analysis : CIC CHU Brabois Nancy
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsors: Cephalon; Cephalon
Recruiting - verified April 2012
ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

Conditions: Ovarian; Primary Peritoneal; Serous Carcinoma; Triple-Negative Breast; Fallopian Tube
Interventions: Drug: ABT-888 with Cyclophospharmide; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Condition: Rheumatoid Arthritis
Intervention:
Sponsors: TcLand Expression S.A.; TcLand Expression S.A.; Premier Research Group plc; Theradis pharma; Medpharmgene Inc.
Recruiting - verified October 2011
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Intervention: Drug: Tivozanib
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011
A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Reslizumab; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified April 2012
Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012
Youth Lifestyle Intervention With Food and Exercise

Conditions: Healthy; Obesity
Interventions: Behavioral: 2 servings of dairy/day and exercise counselling; Behavioral: 4 servings of dairy/day and exercise counselling
Sponsors: McGill University; McGill University; Dairy Farmers of Canada
Recruiting - verified March 2012
Congenital Heart Adolescents: Program of Transition Evaluation Research

Condition: Congenital Heart Defects
Interventions: Behavioral: Clinic-based Educational Intervention; Other: Usual Care
Sponsors: University of Alberta; University of Alberta; Women and Children's Health Research Institute, Canada; Stollery Children's Hospital Foundation
Recruiting - verified January 2012
Prospective Metabolic Monitoring of Youth and Adults With Bipolar Disorder

Conditions: Bipolar Disorder; Youth; Adults
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Pfizer
Recruiting - verified July 2011
Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21

Condition: Pregnancy
Intervention:
Sponsors: OVO R & D; OVO R & D
Recruiting - verified April 2012
Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Condition: Cancer
Intervention: Drug: BMS-906024
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Phase 1 and 2 Study of PX-866 and Cetuximab

Conditions: Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab; Drug: Cetuximab; Drug: PX-866 and cetuximab; Drug: Cetuximab
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified April 2012
PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

Conditions: Venous Thromboembolism; Postpartum
Interventions: Drug: Dalteparin Sodium; Drug: 0.9% Bacteriostatic Sodium Chloride
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified March 2012
The Canadian Multicentre CSF Monitoring and Biomarker Study

Condition: Spinal Cord Injury
Intervention: Other: Crossover of vasopressors
Sponsors: University of British Columbia; University of British Columbia; Rick Hansen Foundation
Recruiting - verified October 2011
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS; Drug: Hydroxyurea; Drug: Aspirin
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Roche Pharma AG
Recruiting - verified December 2011
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS; Drug: Aspirin
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Roche Pharma AG
Recruiting - verified February 2012
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases

Condition: Bone Metastases
Interventions: Drug: Dexamethasone; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified March 2012
A Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Conditions: MDS; CMML; AML
Intervention: Drug: SGI-110
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified November 2011
High Dose Insulin Therapy to Improve Liver Function

Condition: Hepatitis C Virus
Intervention: Drug: Insulin
Sponsors: McGill University Health Center; McGill University Health Center
Recruiting - verified August 2011
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Condition: Polycythemia Vera
Interventions: Drug: INC424 tablets; Other: Best Available Therapy (BAT)
Sponsors: Incyte Corporation; Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Conditions: Neoplasm Metastases; Hepatic Insufficiency
Interventions: Drug: Hepatic dysfunction group; Drug: Control group
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; PharmaMar
Recruiting - verified April 2012
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
Cross-sectional Characterization of Idiopathic Bronchiectasis

Conditions: Idiopathic Bronchiectasis; Nontuberculous Mycobacterium (NTM) Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011
Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel

Condition: Prostate Cancer
Interventions: Drug: cediranib maleate; Drug: dasatinib
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011
Comparing Urinary Tract Infections in Children With Spina Bifida Using Two Types of Catheters for Catheterization

Conditions: Neurogenic Bladder; Spina Bifida
Intervention: Device: Intermittent catheterization
Sponsors: University of Alberta; University of Alberta
Recruiting - verified December 2011
Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: brivanib alaninate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

Condition: Gastroparesis
Interventions: Drug: GSK962040 (5 mg tablet); Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Effects of Canola Oil on Blood Vessel Function in Peripheral Arterial Disease

Condition: Peripheral Arterial Disease
Interventions: Other: traditional canola oil; Other: high oleic canola oil; Other: soybean oil; Other: high linoleic safflower oil; Other: coconut oil; Other: traditional canola oil; Other: safflower oil
Sponsors: University of Manitoba; University of Manitoba; St. Boniface General Hospital Research Centre
Recruiting - verified December 2011
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Polymorphisms and Busulfan PK Study

Condition: Any Disease in Children Who Receive a Stem Cell Transplantation With Busulfan IV
Intervention:
Sponsors: Swiss Pediatric Oncology Group; Swiss Pediatric Oncology Group; European Group for Blood and Marrow Transplantation
Recruiting - verified February 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients

Conditions: Shock, Hemorrhagic; Shock, Traumatic; Acidosis, Lactic
Interventions: Drug: MP4OX; Drug: Saline
Sponsors: Sangart; Sangart
Recruiting - verified May 2012
Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)

Condition: Cervical Spondylotic Myelopathy
Interventions: Drug: riluzole; Drug: Placebo medication
Sponsors: SpineNet; SpineNet
Recruiting - verified April 2012
GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012
Vitamin D and the Health of Blood Vessels in Kidney Disease

Condition: Chronic Kidney Disease (CKD)
Interventions: Dietary Supplement: Dietary supplement; Dietary Supplement: Vitamin D; Dietary Supplement: Vitamin D
Sponsors: University of British Columbia; University of British Columbia; The Kidney Foundation of Canada; Pfizer
Recruiting - verified February 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Biological: adalimumab; Drug: prednisone; Drug: azathioprine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma

Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: LBH589; Drug: Rituximab
Sponsors: Jewish General Hospital; Sarit Assouline; Quebec Clinical Research Organization in Cancer; Novartis; Hoffmann-La Roche
Recruiting - verified December 2011
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

Condition: Colitis, Ulcerative
Interventions: Drug: placebo; Drug: MultiStem low dose; Drug: placebo; Drug: MultiStem low dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose; Drug: placebo; Drug: MultiStem high dose
Sponsors: Pfizer; Pfizer; Athersys, Inc
Recruiting - verified April 2012
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib

Condition: Chronic Myeloid Leukemia
Intervention: Procedure: Stem Cell and Mutational Assay
Sponsors: University of British Columbia; University of British Columbia; Bristol-Myers Squibb
Recruiting - verified November 2011
Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy

Condition: Locally Advanced Breast Cancer (LABC)
Intervention: Procedure: FLT PET and BOLD MRI scan
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG)
Recruiting - verified March 2012
A Non-drug Study Profiling Asthma

Conditions: Asthma; Health
Intervention: Other: All patients
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012
Bosutinib For Autosomal Dominant Polycystic Kidney Disease

Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Bosutinib; Drug: Bosutinib; Drug: Placebo; Drug: Bosutinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Oxidative Stress and Nutritional Supplementation Intervention Study

Conditions: Oxidative Stress; Inflammation; Aging; Dementia; Pain
Intervention: Dietary Supplement: secoisolariciresinol diglucoside
Sponsors: University of Saskatchewan; University of Saskatchewan; Saskatchewan Health Research Foundation
Recruiting - verified October 2011
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
One-Time DNA Study for Vasculitis

Conditions: Churg-Strauss Syndrome; Giant Cell Arteritis; Granulomatosis With Polyangiitis (Wegener's); Microscopic Polyangiitis; Polyarteritis Nodosa; Takayasu's Arteritis
Intervention:
Sponsors: Boston University; Boston University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Office of Rare Diseases (ORD); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery

Condition: Glaucoma
Intervention: Drug: Bevacizumab
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Recruiting - verified June 2011
Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis

Conditions: End-stage Renal Disease (ESRD); Kidney Disease
Interventions: Other: DIANEAL; Other: EXTRANEAL
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Heart and Stroke Foundation of Ontario
Recruiting - verified July 2011
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012
Study the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

Conditions: Myocardial Perfusion Imaging; Myocardial Ischemia
Interventions: Drug: Placebo; Drug: Ranolazine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)

Conditions: Parkinson Disease; Idiopathic Parkinson Disease
Interventions: Drug: Preladenant; Drug: Rasagiline; Drug: Placebo to preladenant; Drug: Placebo to rasagiline
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified May 2012
BIBF 1120 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: multitargeted tyrosine kinase inhibitor BIBF 1120
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of Insulin Lispro in Patients With Inadequately Controlled Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin lispro; Drug: Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
Sponsors: Alexion Pharmaceuticals; Alexion Pharmaceuticals
Recruiting - verified August 2011
Natural History Study of SCID Disorders

Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified November 2011
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cediranib maleate; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified October 2010
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Study Using Plasma for Patients Requiring Emergency Surgery

Conditions: Hemorrhagic Shock; Blood Coagulation Disorders; Blood Products; Trauma; Ruptured AAA
Intervention: Drug: Human Plasma
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified July 2011
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Condition: Severe Hemophilia A
Interventions: Drug: rFVIIIFc; Drug: rFVIIIFc; Drug: rFVIIIFc
Sponsors: Biogen Idec; Biogen Idec; Swedish Orphan Biovitrum
Recruiting - verified March 2012
Changes in Cerebral Blood Flow With Spinal Manipulative Therapy vs. Voluntary Motion

Conditions: Vertebral Artery Dissection; Cerebrovascular Accident; Cerebrovascular Stroke
Intervention: Other: head positions and spinal manipulation
Sponsors: Canadian Memorial Chiropractic College; Canadian Memorial Chiropractic College; Canadian Chiropractic Protective Association; NCMIC
Not yet recruiting - verified June 2011
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Condition: Hemophilia A
Intervention: Biological: OBI-1
Sponsors: Inspiration Biopharmaceuticals, Inc.; Inspiration Biopharmaceuticals, Inc.
Recruiting - verified April 2012
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload

Condition: Cardiac Iron Overload
Intervention: Drug: Deferasirox and Deferoxamine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
AMG 386 in Treating Patients With Persistent or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Biological: trebananib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury

Condition: Acute Kidney Injury
Intervention:
Sponsors: Astute Medical, Inc.; Astute Medical, Inc.
Recruiting - verified March 2012
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Mabthera intravenous; Drug: MabThera subcutaneous
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Combining LHu With Ultrasound Monitoring in IUI

Condition: Infertility
Intervention: Device: urine LH testing
Sponsors: OVO R & D; OVO R & D; Pendopharm
Recruiting - verified August 2011
The CHIPS Trial (Control of Hypertension In Pregnancy Study)

Condition: Gestational Hypertension
Interventions: Procedure: Intervention is blood pressure management approach; Procedure: Intervention is blood pressure management approach.
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR); Sunnybrook Research Institute
Recruiting - verified December 2011
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence

Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Conventional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients

Condition: Prostate Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified March 2012
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

Condition: Hereditary Hemorrhagic Telangiectasia
Intervention:
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2012
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

Condition: Diabetes Mellitus, Type 2
Intervention: Device: Insulin Pump (Medtronic Minimed Paradigm® VEO)
Sponsors: Medtronic; Medtronic
Recruiting - verified March 2012
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Condition: Myocardial Infarction
Interventions: Drug: Eplerenone; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin

Condition: Type 2 Diabetes Mellitus
Interventions: Other: Remote Blood Glucose Monitoring; Other: Continuous Glucose Monitoring; Other: SMBG; Other: SMBG With Knowledge
Sponsors: Endocrine Research Society; Endocrine Research Society
Recruiting - verified August 2010
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: AT9283
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified September 2011
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Testing Objective Methods for Template Matching Ventricular Tachycardia and Pacemapping

Condition: Ventricular Tachycardia
Intervention:
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Recruiting - verified July 2010
Use of Bevacizumab in Trabeculectomy Surgery

Conditions: Glaucoma; Optic Neuropathy; Fibrosis
Interventions: Drug: Bevacizumab; Drug: Control
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Glaucoma Research Society of Canada
Recruiting - verified July 2011
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: G-CSF (filgrastim) plus Plerixafor Injection; Drug: G-CSF (filgrastim) plus Plerixafor Injection
Sponsors: Genzyme; Genzyme
Recruiting - verified April 2012
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
Study Evaluating Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Metastatic Breast Cancer Patients

Conditions: Advanced Solid Tumours; Breast Cancer
Interventions: Drug: pantoprazole sodium for injection; Drug: doxorubicin hydrochloride injection
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified March 2012
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Conditions: Neoplasms; Breast Neoplasms; Breast Cancer
Interventions: Drug: AZD8931; Drug: anastrozole; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Conditions: Blood and Marrow Transplant (BMT); Lymphomas: Non-Hodgkin; Peripheral T-Cell
Intervention: Drug: Nilotinib
Sponsors: Stanford University; Stanford University; Novartis
Recruiting - verified October 2011
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis

Conditions: Cystic Fibrosis; Pancreatic Insufficiency
Interventions: Procedure: Abdominal Ultrasound; Other: Sample collection procedures
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Cystic Fibrosis Foundation
Recruiting - verified April 2012
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Conditions: Sickle Cell Disease; Vaso-occlusive Crisis; Pain Crisis
Interventions: Drug: GMI-1070; Drug: Placebo
Sponsors: GlycoMimetics Incorporated; GlycoMimetics Incorporated
Recruiting - verified March 2012
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified June 2011
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Condition: Phenylketonuria
Interventions: Drug: Sapropterin dihydrochloride; Drug: Placebo
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified November 2011
Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control?

Conditions: Obesity; Obstructive Sleep Apnea
Intervention:
Sponsors: Katz, Sherri Lynne, M.D.; Katz, Sherri Lynne, M.D.; Canadian Institutes of Health Research (CIHR)
Recruiting - verified June 2011
Genetics of the Early and Late Response to Allergen Challenge

Conditions: Asthma; Allergic Rhinitis
Intervention:
Sponsors: University of British Columbia; University of British Columbia; Allergy, Genes and Environment Network (AllerGen); Networks of Centres of Excellence (NCE)
Recruiting - verified November 2011
Molecular Phenotypes for Cystic Fibrosis Lung Disease

Conditions: Cystic Fibrosis; Lung Diseases
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
PRE-DETERMINE Cohort Study

Conditions: Coronary Artery Disease; Left Ventricular Dysfunction; Sudden Cardiac Death
Intervention:
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI); St. Jude Medical; Northwestern University
Recruiting - verified July 2011
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

Condition: Oral Cavity Cancer
Intervention: Drug: PF-00299804/Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Pfizer
Recruiting - verified September 2011
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2012
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520 AM3)

Condition: Fungal Infection
Interventions: Drug: posaconazole; Drug: Dextrose 5% in water (1) posaconazole (2); Drug: posaconazole; Drug: posaconazole; Drug: posaconazole; Drug: Posaconazole
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada

Condition: Chronic Hepatitis C - Genotype 3
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified February 2010
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer

Condition: Kidney Cancer
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified September 2011
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Condition: Malignant Pleural Mesothelioma
Interventions: Drug: NGR-hTNF plus Best Investigator Choice (BIC); Drug: Placebo plus Best Investigator Choice (BIC)
Sponsors: MolMed S.p.A.; MolMed S.p.A.
Recruiting - verified December 2011
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Recruiting - verified January 2012
Onset of Labor and Metabolomics (GEM-2)

Condition: Pregnancy
Intervention:
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke
Recruiting - verified March 2012
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy

Condition: Lung Cancer
Interventions: Drug: MET/VEGFR2 inhibitor Foretinib; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified March 2012
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011
Simvastatin Therapy for Moderate and Severe COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: simvastatin; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Condition: Recurrent or Refractory Pediatric Ependymoma
Interventions: Drug: erlotinib; Drug: etoposide
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; Astellas Pharma Global Development, Inc.
Recruiting - verified February 2012
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization

Conditions: Multiple Myeloma; Lymphoma
Interventions: Drug: Plerixafor; Other: Observation: Nonintervention
Sponsors: CancerCare Manitoba; CancerCare Manitoba
Recruiting - verified February 2012
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q

Condition: Anemia
Interventions: Drug: Lenalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women

Conditions: Postmenopause; Overweight
Interventions: Behavioral: Placebo + exercise; Dietary Supplement: Phytoestrogens without exercise; Other: Phytoestrogens + exercise; Other: Placebo without exercise
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Canadian Institutes of Health Research (CIHR); Centre de recherche sur le vieillissement du CSSS-IUGS
Recruiting - verified June 2010
The International Nocturnal Oxygen (INOX) Trial

Conditions: Chronic Obstructive Pulmonary Disease; Nocturnal Desaturation
Interventions: Device: Concentrator; Device: Sham concentrator
Sponsors: Laval University; Laval University; Canadian Institutes of Health Research (CIHR)
Recruiting - verified February 2012
Improving the Results of Heart Bypass Surgery Using New Approaches to Surgery and Medication

Condition: Coronary Artery Disease
Interventions: Procedure: No-touch SVG harvest vs conventional SVG harvest technique; Dietary Supplement: Fish oil supplementation vs placebo
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Hamilton Health Sciences Corporation
Recruiting - verified November 2011
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis

Condition: Colitis, Ulcerative
Intervention: Drug: GSK1399686
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

Condition: Mild to Moderate Ulcerative Colitis
Interventions: Drug: ORE1001; Drug: Placebo
Sponsors: Ore Pharmaceuticals, Inc.; Ore Pharmaceuticals, Inc.
Recruiting - verified June 2011
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of the Safety and Efficacy of CNTO 328 in Combination With Best Supportive Care Compared With Best Supportive Care in Patients With Multicentric Castleman's Disease

Condition: Castleman's Disease
Interventions: Drug: Placebo; Drug: CNTO 328
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab

Condition: Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)
Interventions: Procedure: Cardiac MRI; Biological: Biomarker Testing
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Hoffmann-La Roche
Recruiting - verified August 2011
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

Conditions: Hematologic Malignancy; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Hodgkin's Disease
Intervention: Drug: Ciclopirox Olamine
Sponsors: University Health Network, Toronto; University Health Network, Toronto; The Leukemia and Lymphoma Society
Recruiting - verified April 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.; Merck
Recruiting - verified April 2012
A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)

Conditions: Renal Cell Carcinoma; Cardiotoxicity; Heart Failure; Hypertension
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012
Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research

Conditions: Breast Cancer; Heart Failure
Intervention: Drug: perindopril OR bisoprolol OR placebo
Sponsors: Alberta Health Services; University of Alberta
Recruiting - verified April 2012
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Restenosis Following Paclitaxel Eluting Balloon Angioplasty of Hemodialysis Access Stenosis

Condition: Renal Failure
Interventions: Device: Percutaneous Transluminal Angioplasty (PTA); Device: Paclitaxel Eluting Balloon Angioplasty
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified January 2012
Docosahexaenoic Acid (DHA) Nutritional Supplementation to Prevent Age-related Macular Degeneration (AMD)

Condition: Age-related Macular Degeneration
Intervention: Dietary Supplement: Ocean Nutrition MEG3 4020EE product
Sponsors: University of Alberta; Yves Sauve; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified November 2011
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Thromboembolism; Venous Thrombosis
Interventions: Drug: edoxaban tosylate(DU-176b); Drug: low molecular weight heparin/unfractionated heparin; Drug: warfarin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified February 2012
Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Intervention: Other: Needle core biopsies of liver metastasis
Sponsors: Jewish General Hospital; Jewish General Hospital; Quebec Clinical Research Organization in Cancer; Fonds de la Recherche en Santé du Québec
Recruiting - verified September 2011
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Conditions: Chronic Allograft Nephropathy; Chronic Kidney Disease; Chronic Renal Failure; Disordered Mineral Metabolism; End Stage Renal Disease; Hyperparathyroidism; Hypophosphatemia; Kidney Disease; Kidney Transplantation; Post Renal Transplantation
Interventions: Drug: Cinacalcet; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels

Conditions: Heart Failure; Elevated Serum Uric Acid
Interventions: Drug: allopurinol; Drug: sugar pill
Sponsors: Duke University; Duke University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Impact of Autologous Platelet Rich Plasma on Healing of Rotator Cuff Repairs

Condition: Rotator Cuff Pathology
Interventions: Other: Platelet Rich Plasma; Other: Platelet Rich plasma
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Hand and Upper Limb Clinic, Canada; St. Joseph's Health Care London
Recruiting - verified July 2011
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox; Drug: Deferasirox placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Condition: Idiopathic Venous Thromboembolism
Intervention: Other: Application of the"Men continue and HER DOO2" rule
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Biomerieux
Recruiting - verified July 2011
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index

Conditions: Deglutition Disorders; Esophageal Diseases; Eosinophilia
Intervention: Other: assessment of disease activity using the EEsAI
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; Institute of Social and Preventive Medicine, University Bern; Dept. of Gastroenterology, Kantonsspital Olten, Olten; Luzerner Kantonsspital; Mayo Clinic Rochester, Minnesota, USA; University of Cincinnati; University of Colorado, Denver; Northwestern University of Chicago, Illinois, USA; Indiana University School of Medicine; Philadelphia University
Recruiting - verified March 2012
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine; Drug: 5-Azacytidine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Conditions: Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
The Prevalence of Thiamin Deficiency in Ambulatory Patients With Heart Failure

Condition: Heart Failure
Intervention:
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Canadian Foundation for Dietetic Research (CFDR)
Recruiting - verified September 2011
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pre-eclampsia and Metabolomics

Condition: Preeclampsia
Intervention:
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Fondation des étoiles
Recruiting - verified March 2012
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

Conditions: Metabolic Disorders; Hematologic, Immune, or Bone Marrow Disorders; Hemoglobinopathies
Interventions: Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan; Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan; Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan; Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
Sponsors: Washington University School of Medicine; Washington University School of Medicine; St. Louis Children's Hospital
Recruiting - verified June 2011
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

Conditions: Pregnancy; Thrombophilia; Pregnancy Complications
Interventions: Drug: dalteparin sodium 5,000 IU prefilled syringes (antenatal); Drug: dalteparin sodium (after delivery - Control group)
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified July 2011
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Conditions: Purpura, Thrombocytopenic, Idiopathic; Immune Thrombocytopenic Purpura
Interventions: Drug: eltrombopag; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders

Conditions: Hematological Malignancy; Bone Marrow Failure Syndrome
Interventions: Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders; Radiation: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders; Procedure: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack

Conditions: Ischemic Stroke; Transient Ischemic Attacks
Interventions: Drug: Antihypertensive agents and lipid lowering therapy; Other: Usual Care
Sponsors: University of Alberta; University of Alberta; Heart and Stroke Foundation; Alberta Heritage Foundation for Medical Research
Recruiting - verified December 2011
Eslicarbazepine Acetate Monotherapy Long Term Study

Condition: Epilepsy
Intervention: Drug: Eslicarbazepine acetate
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified April 2012
RCT Comparing Ion Levels and Clinical Outcomes of A-Class BFH to Metal on Polyethylene Total Hip Replacement

Conditions: Hip Joint; Osteoarthritis; Arthroplasty
Interventions: Device: A Class BFH; Device: Metal on Polyethylene
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Wright Medical Technology
Recruiting - verified October 2011
Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery

Conditions: Atrial Fibrillation; Mitral Valve Insufficiency; Mitral Valve Stenosis
Interventions: Device: Mitral valve surgery with ligation/excision of left atrial appendage with ablation; Procedure: Mitral valve surgery with ligation/excision of left atrial appendage
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Neurological Disorders and Stroke (NINDS); Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2012
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab

Condition: Glaucoma
Interventions: Drug: ranibizumab; Procedure: standard care
Sponsors: Maisonneuve-Rosemont Hospital; Maisonneuve-Rosemont Hospital; Novartis
Recruiting - verified April 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

Conditions: Psoriasis; Atopic Dermatitis
Interventions: Other: Blood pressure; Other: Height; Other: Weight; Other: BMI; Other: Waist Circumference
Sponsors: Northwestern University; Northwestern University
Recruiting - verified September 2011
Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier

Condition: Thoracic Aortic Vascular Disease
Intervention: Procedure: Repair of descending thoracic aneurysm and morphine
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Recruiting - verified April 2009
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Family Intervention for Obese Children Using Portion Control Strategy for Weight Control

Condition: Obesity
Interventions: Other: Nutrition counseling + portion control tool; Other: Nutrition counseling
Sponsors: University of Calgary; University of Calgary
Recruiting - verified October 2011
Alberta Clinical Trial in Optimizing Hypertension

Condition: Hypertension
Interventions: Other: Enhanced pharmacist care; Other: Usual Care
Sponsors: University of Alberta; University of Alberta; Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2012
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial

Condition: Cardiac Arrest
Interventions: Procedure: Therapeutic Hypothermia; Procedure: Therapeutic Normothermia
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial

Condition: Cardiac Arrest
Interventions: Procedure: Therapeutic Hypothermia; Other: Therapeutic Normothermia
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol

Conditions: Coronary Artery Disease; Mitral Valve Regurgitation; Mitral Valve Incompetence; Heart Failure
Intervention: Device: CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified March 2012
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer

Conditions: Cancer of the Prostate; Prostate Cancer; Prostatic Neoplasms
Interventions: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E; Drug: Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified September 2011
Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates

Condition: Cholestasis
Interventions: Drug: Ursodiol; Drug: placebo
Sponsors: St. Justine's Hospital; St. Justine's Hospital
Recruiting - verified July 2011
Home-Based Walking Study

Conditions: Cardiovascular; Diabetes; Orthostatic Hypotension; Type 2 Diabetes
Intervention: Behavioral: Home-based walking program (Aerobic Exercise)
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Conditions: Fungemia; Neutropenia; Candidiasis
Interventions: Drug: Active Anidulafungin; Drug: Active Caspofungin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation

Conditions: Mitral Valve Insufficiency; Coronary Artery Disease
Interventions: Procedure: Mitral Valve Repair; Procedure: CABG
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2012
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Micronutrients and Antioxidants in HIV Infection

Condition: HIV Infection
Interventions: Dietary Supplement: Micronutrients and antioxidants; Dietary Supplement: Multivitamins and minerals
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian HIV Trials Network; Ontario HIV Treatment Network
Recruiting - verified July 2011
Nilotinib Versus Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Pts With Evidence of Persistent Leukemia by RQ-PCR (ENESTcmr)

Condition: CHRONIC MYELOGENOUS LEUKEMIA
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

Condition: Intraventricular Hemorrhage
Interventions: Drug: Cathflo Activase; Other: Normal saline
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute of Neurological Disorders and Stroke (NINDS); Genentech
Recruiting - verified July 2009
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study to Determine The Effect of a Drug Called Neupogen on Stroke Recovery

Condition: Ischemic Stroke
Intervention: Drug: Filgrastim
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified October 2011
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism
Interventions: Device: Comprehensive computed tomography of the abdomen/pelvis; Other: Limited Malignancy Screening
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified October 2011
Stone Centre Urine and Serum Bank

Condition: Urinary Stone Disease
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca

Conditions: Locally Advanced Breast Cancer; Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified September 2011
Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease

Condition: Kidney Diseases
Interventions: Behavioral: High/ Low Phosphate diet; Behavioral: High/ Low Phosphate diet; Behavioral: High/ Low Phosphate diet
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified April 2012
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome

Condition: Schizophrenia and Disorders With Psychotic Features
Intervention: Drug: Ziprasidone HCL (oral)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Immediate Management of the Patient With Aneurysm Rupture : Open Versus Endovascular Repair

Condition: Abdominal Aortic Aneurysm
Interventions: Procedure: Open repair; Procedure: EVAR
Sponsors: Imperial College London; Imperial College London; London School of Hygiene and Tropical Medicine; University of Cambridge; The Leeds Teaching Hospitals NHS Trust; St George's, University of London
Recruiting - verified January 2012
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: environmental carcinogenesis study; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Condition: Myelogenous Leukemia, Chronic
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

Condition: Pulmonary Tuberculosis
Interventions: Drug: rifampin; Drug: rifapentine; Drug: rifapentine; Drug: rifapentine
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Sanofi-Aventis
Recruiting - verified May 2012
Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors

Condition: Liver Tumors
Intervention: Radiation: Stereotactic Body Radiation Therapy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified August 2011
Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery

Conditions: Cataract; Phacoemulsification; Mydriasis; Pseudoexfoliation Syndrome
Intervention: Procedure: Intracameral injection of mydriatic agent
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Recruiting - verified May 2008
Intron A for the Treatment of Hypertrophic Scar

Conditions: Burn; Hypertrophic Scar
Interventions: Drug: interferon alpha 2b; Drug: placebo
Sponsors: University of Alberta; University of Alberta
Not yet recruiting - verified November 2011
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Conditions: Bone Metastases; Multiple Myeloma
Interventions: Device: ExAblate 2000; Device: Sham
Sponsors: InSightec; InSightec
Recruiting - verified October 2011
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial of IntensiVE Dialysis

Conditions: Renal Replacement Therapy; Renal Dialysis; End Stage Kidney Disease; End Stage Renal Disease; Uremia
Intervention: Procedure: haemodialysis
Sponsors: The George Institute; The George Institute; National Health and Medical Research Council, Australia; Baxter Healthcare Corporation
Recruiting - verified March 2012
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

Condition: Hematologic Neoplasms
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2011
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010
Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease

Condition: Non-alcoholic Fatty Liver Disease
Intervention: Procedure: Phlebotomy
Sponsors: University of Western Ontario, Canada; University of Western Ontario, Canada
Recruiting - verified August 2011
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified August 2010
PRET: Patients Prone to Recurrence After Endovascular Treatment

Conditions: Intracranial Aneurysm; Subarachnoid Hemorrhage
Intervention: Procedure: endovascular coil embolization
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM)
Recruiting - verified January 2012
Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Bortezomib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada; Ortho Biotech, Inc.
Recruiting - verified October 2011
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Conditions: Transfusional Iron Overload; Transfusional Hemosiderosis
Interventions: Drug: Deferasirox; Drug: Deferoxamine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Capsule Endoscopy vs Standard of Care for Obscure Intestinal Bleeding

Condition: Iron Deficiency Anemia
Interventions: Device: Diagnostic Test - Given Imaging Pillcam; Other: Diagnostics
Sponsors: University of Calgary; University of Calgary; Alberta Heritage Foundation for Medical Research; Calgary Health Region
Recruiting - verified December 2011
Improvement of Patients With Chronic Heart Failure Using NT-proBNP

Condition: Congestive Heart Failure
Intervention: Other: NT-proBNP guided care
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Hoffmann-La Roche
Recruiting - verified July 2009
Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)

Conditions: Vertebrobasilar Insufficiency; Ischemic Attack, Transient; Cerebrovascular Disorder; Brain Ischemia; Stroke
Intervention:
Sponsors: University of Illinois; Sepideh Amin-Hanjani; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
The Effect of an Exercise Program on Physical Function After a Spinal Cord Injury

Condition: Spinal Cord Injury
Interventions: Behavioral: Cardiovascular training; Behavioral: Balance training
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified April 2012
IGIV Study for Chronic ITP Patients Ages 3-70

Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Biological: IGIV3I Grifols 10%
Sponsors: Grifols Biologicals Inc.; Grifols Biologicals Inc.
Recruiting - verified April 2012
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Condition: Brain Tumors
Intervention: Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Sponsors: New York University School of Medicine; New York University School of Medicine; Children's Hospitals and Clinics of Minnesota; Schneider Children's Hospital
Recruiting - verified January 2012
Heparin-Induced Thrombocytopenia Score Card Study

Condition: Heparin-Induced Thrombocytopenia
Interventions: Device: ID-PaGIA Heparin/PF4 antibody test; Procedure: Clinical Prediction Score-HIT Score Card
Sponsors: McMaster University; McMaster University; Heart and Stroke Foundation of Ontario
Recruiting - verified May 2012
Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression

Condition: Bipolar II Depression
Interventions: Drug: Lamotrigine plus plus antidepressant medication subjects were prescribed prior to study entry; Drug: Lamotrigine
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified March 2012
Inflammatory Breast Cancer (IBC) Registry

Condition: Breast Cancer
Interventions: Other: Interview; Procedure: Blood and Tissue Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Efficacy of Islet After Kidney Transplantation

Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Islet transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011
LEA29Y (Belatacept) Emory Edmonton Protocol

Condition: Type 1 Diabetes Mellitus
Interventions: Procedure: Islet transplant; Drug: Belatacept; Drug: Basiliximab; Drug: Mycophenolate Mofetil
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011
The Effect of a Diabetes Action Team in Patients Post Infrainguinal Bypass Surgery With and Without Diabetes

Conditions: Type 2 Diabetes; Peripheral Vascular Disease
Interventions: Behavioral: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician; Behavioral: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team; Behavioral: Subjects without diabetes will have their blood glucose levels monitored while in the hospital
Sponsors: University of British Columbia; University of British Columbia; Novo Nordisk
Recruiting - verified December 2011
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

Conditions: Tumor Antigen-positive Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Biological: Immunotherapeutic GSK1572932A; Drug: Cisplatin (CDDP); Drug: Vinorelbine; Procedure: Radiotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified October 2011
Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: glyburide; Drug: GlucoNorm
Sponsors: University of British Columbia; University of British Columbia; Novo Nordisk
Recruiting - verified February 2012
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment

Condition: Locally Advanced Breast Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012
Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF

Conditions: Atrial Fibrillation; Catheter Ablation
Intervention: Other: Aggressive BP lowering
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada; Nova Scotia Health Research Foundation
Recruiting - verified September 2009
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Conditions: Invasive Fungal Infection; Aspergillosis
Interventions: Drug: Isavuconazole; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients

Condition: Type 2 Diabetes
Interventions: Procedure: laparoscopic gastric bypass surgery; Procedure: laparoscopic adjustable gastric banding; Procedure: Intensive Medical Management
Sponsors: McMaster University; Hamilton Health Sciences Corporation
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Resistance Exercise in Already-active Diabetic Individuals (READI) Trial

Condition: Diabetes
Intervention: Behavioral: Resistance Exercise
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified May 2012
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
A Randomized Trial of Unruptured Brain AVMs

Condition: Unruptured Brain Arteriovenous Malformation
Intervention: Procedure: invasive therapy [endovascular procedures, neurosurgery, or radiotherapy, alone or in combination]
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified September 2011
Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes

Conditions: Cardiovascular; Diabetic
Interventions: Behavioral: Aerobic Exercise and Strength Exercise; Behavioral: Strength training
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR)
Recruiting - verified December 2011
Preoperative Treatment of Patients With High Risk Thymoma

Condition: Thymoma
Interventions: Drug: cisplatin and etoposide; Procedure: Surgical Resection; Radiation: Concurrent Radiotherapy
Sponsors: Valley Health System; Valley Health System
Recruiting - verified August 2011
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room

Condition: Coronary Artery Disease
Interventions: Procedure: Robotic-assisted Coronary Surgical Revascularization; Procedure: PCI- Drug Eluting Stents
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Canada Foundation for Innovation; Ontario Innovative Trust; Ontario Research and Development Challenge Fund
Recruiting - verified August 2011
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
Fetal Aortic Pulsewave Velocity: A Novel Doppler Ultrasound Method of Measuring the Biophysical Properties of the Fetal Aorta

Condition: Healthy
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified December 2011
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Determining Disease Activity Biomarkers in Individuals With Churg-Strauss Syndrome

Condition: Churg-Strauss Syndrome
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Determining Disease Activity Biomarkers in Individuals With Polyarteritis Nodosa

Condition: Polyarteritis Nodosa
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis

Condition: Temporal Arteritis
Intervention:
Sponsors: Boston University; Peter A. Merkel; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis

Conditions: Granulomatosis With Polyangiitis; Microscopic Polyangiitis; Wegener's
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Randomized On-X Anticoagulation Trial

Condition: Heart Valve Disease
Interventions: Device: On-X valve using reduced anticoagulation; Device: On-X Valve with Standard Coumadin Therapy
Sponsors: Medical Carbon Research Institute, LLC; Medical Carbon Research Institute, LLC
Recruiting - verified June 2011
Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)

Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study

Condition: Hematologic Malignancy
Intervention: Drug: intravenous busulfan
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified September 2011
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

Conditions: Venous Thrombosis; Pulmonary Embolism
Intervention: Drug: Tinzaparin
Sponsors: St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton; Heart and Stroke Foundation of Ontario; LEO Pharma
Recruiting - verified August 2011
Interactive Studies of Endstage Diabetic Dialysis Patients

Condition: Diabetes
Interventions: Procedure: High Hemoglobin Concentration; Procedure: Low Hemoglobin Concentration
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012
How Smoking Causes COPD: Examination of Immune System Changes

Condition: Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton
Recruiting - verified July 2011
Mechanisms of Orthostatic Intolerance in Spinal Cord Injured Individuals and Following Bed Rest

Condition: Spinal Cord Injury
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study

Condition: Autonomic Dysreflexia
Intervention: Drug: Prazosin HCL
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
Detection of Early Lung Cancer by Serum Protein Expression Profiling

Condition: Non-small Cell Lung Cancer
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Biological: OGX-011
Sponsors: University of British Columbia; University of British Columbia; Department of Defense
Recruiting - verified April 2012
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment

Condition: Colon Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Natural History Study of the Development of Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012
Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases

Conditions: Metastatic Cancer; Pain
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); Cancer Research UK; Dutch Bone Metastasis Study Group; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011
Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Biological: sargramostim; Drug: CHOP regimen; Drug: carmustine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate; Procedure: bone marrow ablation with stem cell support; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified February 2009